He barely knew what a hedge fund was, but when a manager from Gerson Lehrman Group approached Gilman in 2001 about becoming a consultant, he was intrigued. He could make the time, he figured, and the money was good. He soon found himself having hundreds of conversations a year with people he normally wouldn’t have had any contact with, cunning traders and analysts interested in different aspects of healthcare, from Parkinson’s disease to multiple system atrophy to Alzheimer’s. They were polite and well-informed, and the questions they asked were flattering to Gilman’s ego, always laced with
...more
